Reuters logo
3 个月内
BRIEF-Aerie Pharmaceuticals reports positive topline safety and efficacy results for rhopressatm
2017年4月12日 / 晚上8点22分 / 3 个月内

BRIEF-Aerie Pharmaceuticals reports positive topline safety and efficacy results for rhopressatm

1 分钟阅读

April 12 (Reuters) - Aerie Pharmaceuticals Inc:

* Aerie Pharmaceuticals reports positive rocket 4 six-month topline safety and efficacy results for rhopressatm (netarsudil ophthalmic solution) 0.02pct

* Aerie Pharmaceuticals -most common rhopressa adverse event was hyperemia, which was reported in about 48 percent of patients, 75 percent of which was mild

* Aerie Pharmaceuticals Inc says 12-month safety data from mercury 1 are expected in Q3 of this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below